Compare Abrdn Physical Platinum Shares ETF (PPLT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs ResMed Inc. — how do they compare? Abrdn Physical Platinum Shares ETF trades at $14.88, while ResMed Inc. trades at $193.21 (market cap $28.40B). The key difference: ResMed Inc. pays a 1.23% dividend while Abrdn Physical Platinum Shares ETF pays none, and Abrdn Physical Platinum Shares ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| PPLT | RMD | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $293.73 |
52-Week Low | $11.78 | $182.82 |
Market Cap | — | $28.40B |
Enterprise Value | — | $27.58B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT trades at $14.47, down 0.21% on the day, with a strong bearish technical signal from moving averages and a neutral stance from oscillators. The stock underwent a 1:10 forward split effective May 18, 2026. Recent news highlights platinum's underperformance versus gold and silver, with some analysts viewing the gap as a potential catch-up opportunity, while others caution after a significant rally.
The outlook is mixed; technicals suggest near-term pressure, but the valuation gap in precious metals could present a long-term opportunity. Key risks include commodity price volatility and the ETF's lack of dividend income. Investor sentiment is divided between those betting on a rebound and those taking profits after strong gains.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
